|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.700 NZD | -0.27% |
|
+2.78% | +9.47% |
| Jan. 14 | New Zealand Shares Fall Amid Easing Geopolitical Tensions, New Tariffs; Ryman Healthcare's Total Fiscal Q3 Sales Volumes Fall | MT |
| Dec. 30 | NZX Biggest Gainers | MT |
Projected Income Statement: AFT Pharmaceuticals Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 113.1 | 130.3 | 156.6 | 195.4 | 208 | 254.6 | 298.1 | 339.7 |
| Change | - | 15.22% | 20.2% | 24.75% | 6.45% | 22.39% | 17.09% | 13.96% |
| EBITDA 1 | 11.81 | 21.43 | 21.39 | 26.25 | 20.88 | 26.84 | 33.91 | 41.92 |
| Change | - | 81.45% | -0.19% | 22.69% | -20.45% | 28.54% | 26.33% | 23.65% |
| EBIT 1 | 10.71 | 20.39 | 19.67 | 24.24 | 17.65 | 23.27 | 29.96 | 37.78 |
| Change | - | 90.41% | -3.53% | 23.21% | -27.18% | 31.86% | 28.77% | 26.07% |
| Interest Paid 1 | -2.821 | -1.704 | -3.87 | -2.216 | -1.614 | -2.1 | -2.1 | -1.8 |
| Earnings before Tax (EBT) 1 | 7.887 | 18.68 | 15.8 | 22.02 | 16.03 | 20.37 | 27.38 | 32.67 |
| Change | - | 136.91% | -15.45% | 39.37% | -27.18% | 27.02% | 34.44% | 19.33% |
| Net income 1 | 7.8 | 19.85 | 10.65 | 15.61 | 11.96 | 15.67 | 20.35 | 26.18 |
| Change | - | 154.46% | -46.32% | 46.51% | -23.36% | 31.01% | 29.82% | 28.66% |
| Announcement Date | 5/23/21 | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | - | - | - |
1NZD in Million
Estimates
Forecast Balance Sheet: AFT Pharmaceuticals Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 35.2 | 29.3 | 29.9 | 16.2 | 14.5 | 19 | 18.2 | 12.5 |
| Change | - | -16.76% | 2.05% | -45.82% | -10.49% | 31.03% | -4.21% | -31.32% |
| Announcement Date | 5/23/21 | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | - | - | - |
1NZD in Million
Estimates
Cash Flow Forecast: AFT Pharmaceuticals Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 6.231 | 5.585 | 9.177 | 9.527 | 6.951 | 8.587 | 6.77 | 7.47 |
| Change | - | -10.37% | 64.32% | 3.81% | -27.04% | 23.53% | -21.16% | 10.34% |
| Free Cash Flow (FCF) 1 | -5.481 | 8.567 | 2.452 | 19.33 | - | - | - | - |
| Change | - | 256.3% | -71.38% | 688.5% | - | - | - | - |
| Announcement Date | 5/23/21 | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | - | - | - |
1NZD in Million
Estimates
Forecast Financial Ratios: AFT Pharmaceuticals Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | 10.44% | 16.45% | 13.66% | 13.43% | 10.04% | 10.54% | 11.37% | 12.34% |
| EBIT Margin (%) | 9.47% | 15.65% | 12.56% | 12.4% | 8.48% | 9.14% | 10.05% | 11.12% |
| EBT Margin (%) | 6.97% | 14.34% | 10.09% | 11.27% | 7.71% | 8% | 9.18% | 9.62% |
| Net margin (%) | 6.9% | 15.23% | 6.8% | 7.99% | 5.75% | 6.16% | 6.82% | 7.71% |
| FCF margin (%) | -4.85% | 6.57% | 1.57% | 9.89% | - | - | - | - |
| FCF / Net Income (%) | -70.27% | 43.16% | 23.01% | 123.86% | - | - | - | - |
Profitability | ||||||||
| ROA | 8.1% | 17.5% | 7.74% | 9.96% | 7.14% | 12.15% | 13.75% | 15.3% |
| ROE | 28.91% | 42.53% | 15.72% | 19.38% | 12.94% | 14.54% | 16.41% | 17.91% |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | 2.98x | 1.37x | 1.4x | 0.62x | 0.69x | 0.71x | 0.54x | 0.3x |
| Debt / Free cash flow | -6.41x | 3.42x | 12.19x | 0.84x | - | - | - | - |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | 5.51% | 4.29% | 5.86% | 4.88% | 3.34% | 3.37% | 2.27% | 2.2% |
| CAPEX / EBITDA (%) | 52.75% | 26.06% | 42.9% | 36.3% | 33.29% | 31.99% | 19.97% | 17.82% |
| CAPEX / FCF (%) | -113.68% | 65.19% | 374.27% | 49.28% | - | - | - | - |
Items per share | ||||||||
| Cash flow per share 1 | 0.00726 | 0.1352 | 0.1109 | 0.2752 | 0.1256 | 0.1465 | 0.1654 | 0.2313 |
| Change | - | 1,762.26% | -17.97% | 148.15% | -54.36% | 16.62% | 12.9% | 39.85% |
| Dividend per Share 1 | - | - | - | 0.016 | 0.018 | 0.0263 | 0.0341 | 0.0418 |
| Change | - | - | - | - | 12.5% | 46.22% | 29.56% | 22.64% |
| Book Value Per Share 1 | 0.3498 | 0.542 | 0.6987 | 0.8372 | 0.9311 | 0.7743 | 0.9367 | 1.147 |
| Change | - | 54.95% | 28.91% | 19.82% | 11.21% | -16.84% | 20.97% | 22.46% |
| EPS 1 | 0.07 | 0.19 | 0.1 | 0.15 | 0.11 | 0.1494 | 0.194 | 0.2496 |
| Change | - | 171.43% | -47.37% | 50% | -26.67% | 35.85% | 29.83% | 28.66% |
| Nbr of stocks (in thousands) | 104,584 | 104,697 | 104,866 | 104,866 | 104,866 | 104,866 | 104,866 | 104,866 |
| Announcement Date | 5/23/21 | 5/22/22 | 5/22/23 | 5/22/24 | 5/21/25 | - | - | - |
1NZD
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E ratio | 24.8x | 19.1x |
| PBR | 4.78x | 3.95x |
| EV / Sales | 1.6x | 1.36x |
| Yield | 0.71% | 0.92% |
EPS & Dividend
Y-o-Y evolution of P/E
Year-on-year evolution of the Yield
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.700NZD
Average target price
4.300NZD
Spread / Average Target
+16.22%
Annual profits - Rate of surprise
- Stock Market
- Equities
- AFT Stock
- Financials AFT Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
